Addyi Cost in South Dakota 2026: Flibanserin Prices, Insurance, and Compounding Options

What Is Addyi and Why Does Cost Vary by State?

Flibanserin (brand name Addyi) is an FDA-approved oral tablet indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval on August 18, 2015, after two prior rejections and a resubmission with a Risk Evaluation and Mitigation Strategy (REMS) program addressing alcohol interaction risk. [1] Pricing and access vary by state because each state Medicaid program independently decides formulary inclusion, and compounding pharmacy networks differ by region.

The approved dose is 100 mg taken orally once at bedtime. Daytime dosing is not recommended because somnolence and hypotension risk increases significantly with waking activity. [1] HSDD affects an estimated 8 to 10 percent of premenopausal women in the United States, making it the most common female sexual dysfunction diagnosis by prevalence. [2]

Flibanserin's mechanism is distinct from erectile-dysfunction drugs. Rather than acting on genital blood flow, it modulates central serotonin (5-HT1A agonist, 5-HT2A antagonist) and dopamine pathways. [3] This central mechanism is why the FDA classified it as a prescription-only agent with mandatory prescriber and pharmacy certification under the REMS program at launch, a requirement that was later modified. Understanding that mechanism matters clinically because it means the drug interacts with CYP3A4 inhibitors and alcohol in ways that a locally acting agent would not.

South Dakota has one licensed Addyi-certified pharmacy network and several independent 503A compounding pharmacies that may prepare flibanserin. Access through telehealth is legal statewide as of 2025.

Addyi Retail Price in South Dakota in 2026

The retail cash price for Addyi in South Dakota is $880 per month, matching the manufacturer wholesale acquisition cost (WAC) set by Sprout Pharmaceuticals. Retail pharmacies in Sioux Falls, Rapid City, and Aberdeen have reported no significant deviation from that WAC in 2026 because generic flibanserin has not yet captured meaningful market share.

The BEGONIA trial (N=1,378, published in the Journal of Sexual Medicine 2014) demonstrated that flibanserin 100 mg nightly increased the number of satisfying sexual events by 0.5 to 1.0 events per month versus placebo, with statistically significant improvements in desire scores and distress. [4] That modest but real efficacy data is what drove FDA approval and, in turn, Sprout's pricing strategy. Sprout has not reduced WAC pricing since 2015, a pattern documented in FDA drug pricing transparency filings. [1]

For context, the 30-tablet (30-day supply) package is the only commercially available unit of measure. There is no half-dose formulation on the market, and splitting tablets is not recommended because the coating affects dissolution. [1]

A GoodRx-type coupon at major South Dakota chain pharmacies (Walgreens, Sanford Pharmacy, Avera pharmacies) may reduce cash price by up to 15 percent in some instances, bringing the effective price to roughly $748 to $770, though this varies month to month. Even with a coupon, the annual out-of-pocket burden approaches $8,900 to $10,560 for uninsured patients.

South Dakota Medicaid Coverage for Addyi

South Dakota Medicaid does not cover Addyi as of the 2026 plan year. The South Dakota Department of Social Services Preferred Drug List excludes flibanserin from both the Medicaid fee-for-service formulary and the Healthy and Well Kids in Iowa (HAWK-I) equivalent programs. [5]

This exclusion is not unique to South Dakota. A 2020 analysis published in Women's Health Issues found that only 12 of 50 state Medicaid programs covered flibanserin, citing lack of clinical necessity documentation pathways. [6] The FDA label itself notes that flibanserin produces a modest effect size. The mean change from baseline in satisfying sexual events per 28-day period in Phase 3 trials was approximately 0.5 to 1.0 events over placebo, and mean desire score improvement on the Female Sexual Function Index was 1.5 to 2.5 points versus placebo. [4]

For South Dakota Medicaid enrollees who want access, the practical options are: seeking a commercial marketplace plan if income qualifies, applying for the Sprout patient assistance program (described below), or consulting a licensed 503A compounding pharmacy.

No South Dakota Medicaid waiver program currently includes flibanserin. Patients should confirm current formulary status directly with South Dakota Department of Social Services at 1-800-597-1603, as formularies can change quarterly. [5]

Commercial Insurance Coverage for Addyi in South Dakota

Commercial insurance coverage in South Dakota is inconsistent and almost always requires prior authorization. Coverage depends on whether a plan treats HSDD as a covered diagnosis under the behavioral health or women's health benefit tier.

The Affordable Care Act mandates coverage of preventive services rated A or B by the U.S. Preventive Services Task Force. HSDD treatment is not on that list, so insurers face no federal mandate to cover flibanserin. [7] As a result, many South Dakota marketplace plans place Addyi on Tier 4 or Tier 5 specialty formulary tiers with 20 to 40 percent coinsurance, meaning patient cost-share can still reach $176 to $352 per month even with coverage.

Major South Dakota commercial insurers including Wellmark Blue Cross Blue Shield and Sanford Health Plan handle prior authorization individually. A prescriber must typically document: a formal HSDD diagnosis using validated criteria (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, DSM-5 criteria), confirmed premenopausal status, absence of a relationship or psychiatric etiology for low desire, and failure or contraindication of non-pharmacologic therapy. [8]

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion 780 states that clinicians "should evaluate and treat sexual dysfunction in women as part of comprehensive sexual health care," but does not mandate a specific first-line pharmacologic treatment. [9] That language gives insurers latitude to require step therapy. Patients and prescribers in South Dakota should submit prior authorization with DSM-5 documentation and at minimum three months of documented behavioral therapy or couples counseling attempts to strengthen the case.

Compounded Flibanserin in South Dakota: Legality and Cost

Compounded flibanserin is legally available through licensed 503A pharmacies in South Dakota and can reduce cost substantially. A 503A pharmacy is a state-licensed, patient-specific compounding pharmacy regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act. [10]

These pharmacies can compound flibanserin from bulk active pharmaceutical ingredient (API) for an individual patient with a valid prescription, provided the compound is not a copy of a commercially available drug under circumstances the FDA deems inappropriate. Because Addyi is a branded drug with no generic equivalent and the compounded version differs in formulation (for example, a sublingual troche versus an oral tablet), 503A pharmacies in South Dakota may legally prepare it. [10] The FDA has not placed flibanserin on the Category 1 (prohibited) or Category 2 (evaluated) 503B list, which is relevant because 503B outsourcing facilities face stricter rules. [11]

Cost through a 503A compounding pharmacy in South Dakota can range from $60 to $200 per month depending on the formulation, the pharmacy's ingredient sourcing, and dispensing fees. Some telehealth platforms that serve South Dakota negotiate compounding pharmacy rates and pass savings to patients, bringing costs toward the lower end of that range. This represents a potential annual savings of $8,160 to $9,840 compared with retail Addyi.

Patients should verify that any compounding pharmacy holds an active South Dakota Board of Pharmacy license. The South Dakota Board of Pharmacy maintains a public licensee lookup at pharmacy.sd.gov. [12] A prescription from a licensed South Dakota provider is required regardless of pharmacy type.

The clinical bioequivalence of compounded flibanserin formulations has not been established in FDA-reviewed trials. The BEGONIA trial data applies specifically to Sprout's 100 mg tablet. [4] Clinicians should counsel patients on this distinction.

Telehealth Access to Flibanserin in South Dakota

Telehealth prescribing of flibanserin is legal in South Dakota. The South Dakota Board of Medical Examiners permits synchronous audio-video telehealth consultations for new patient evaluations and prescription issuance for non-controlled substances. Flibanserin is not a controlled substance. [13]

The federal Ryan Haight Act, which restricts online prescribing of controlled substances, does not apply to flibanserin. [14] A South Dakota patient can therefore receive a valid flibanserin prescription from a licensed South Dakota physician or advanced practice provider via a HIPAA-compliant video visit without a prior in-person examination, subject to the provider's clinical judgment.

Several national telehealth platforms operate in South Dakota and can prescribe flibanserin. Patients in rural South Dakota counties, where the nearest OBGYN or sexual health specialist may be 60 to 100 miles away, benefit most from this pathway. South Dakota has 66 counties; 53 are classified as rural or frontier by the Health Resources and Services Administration. [15]

A complete telehealth HSDD evaluation should include a validated screening instrument. The Female Sexual Distress Scale-Revised (FSDS-R) with a score above 11 combined with a Female Sexual Function Index (FSFI) total score below 26.55 meets the diagnostic threshold used in major HSDD trials. [16] Providers who skip validated scoring and issue prescriptions based on patient self-report alone may face prior authorization denials from insurers requesting clinical documentation.

Sprout Pharmaceuticals Savings Card and Patient Assistance in South Dakota

Sprout Pharmaceuticals offers a savings card for commercially insured patients that may reduce out-of-pocket Addyi cost to $0 per month. South Dakota patients with qualifying commercial insurance can enroll at addyi.com or through their prescribing provider. The savings card does not apply to Medicaid, Medicare, or other federal health program enrollees, consistent with Anti-Kickback Statute restrictions. [17]

Eligibility criteria for the savings card as of 2026: the patient must have a valid commercial prescription drug benefit, the prescription must be for brand-name Addyi (not compounded flibanserin), and the patient must be a U.S. resident. There is no stated income cap for the commercial savings card.

For patients without commercial insurance, Sprout's patient assistance program (PAP) provides Addyi at no cost to patients who meet income guidelines, generally at or below 400 percent of the federal poverty level ($58,320 for an individual in 2025). Applications go through NeedyMeds or directly through Sprout's access support line. [18]

The savings card covers up to 12 monthly fills per calendar year. After that, the patient pays the plan's standard cost-share. Patients should track their fill count and plan for possible out-of-pocket costs in month 13 if they begin the savings card early in the year.

Clinical Efficacy: What the Evidence Actually Shows

Understanding what flibanserin does and does not do helps South Dakota patients and prescribers decide whether $880 per month (or even $100 to $200 for compounded versions) is a reasonable expenditure.

The BEGONIA trial (N=1,378 to 24 weeks) showed that women taking flibanserin 100 mg nightly reported a mean increase of 0.8 satisfying sexual events per 28 days versus 0.5 for placebo (P<0.0001). Desire scores on the FSFI improved by 1.6 points versus 0.9 points for placebo. The Female Sexual Distress Scale score improved by 11.0 points versus 7.9 points for placebo. [4] These are statistically significant differences, but their clinical magnitude is modest.

A 2016 systematic review published in JAMA Internal Medicine (N=5,914 across three Phase 3 trials) found that flibanserin produced 0.5 additional satisfying sexual events per month and a 0.3-point improvement on the desire subscale of the FSFI compared with placebo. [19] The authors noted that 10 percent of women on flibanserin experienced dizziness, 11 percent experienced somnolence, and 2 to 3 percent experienced syncope, particularly when combined with alcohol. [19]

The FDA required a REMS program at approval specifically because of the alcohol interaction risk. [1] A single moderate dose of alcohol consumed within two hours of flibanserin can produce symptomatic hypotension. The FDA label lists alcohol as a contraindication, not merely a warning. [1] South Dakota prescribers using telehealth platforms should ensure this contraindication is documented in the visit note and patient consent.

For women who cannot avoid alcohol entirely, the risk-benefit calculation shifts. The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges this limitation and suggests that women with significant alcohol use should explore alternative or adjunct treatments. [20]

How Flibanserin Compares with Off-Label Alternatives in South Dakota

Flibanserin is the only FDA-approved oral treatment for HSDD in premenopausal women. Bremelanotide (Vyleesi) is FDA-approved for the same indication but is given as a subcutaneous self-injection 45 minutes before anticipated sexual activity, not as a daily oral tablet. [21] Bremelanotide's WAC is approximately $990 per use dose, making it more expensive on a per-episode basis but potentially cheaper for women who have infrequent sexual activity.

Off-label options sometimes used in South Dakota include low-dose testosterone (not FDA-approved for women but supported by the International Society for the Study of Women's Sexual Health position statement) and bupropion. [22] Neither has the FDA-approved HSDD indication, and insurers are even less likely to cover them for this purpose. The FDA has not approved any testosterone product for HSDD in women, though the Endocrine Society guideline allows for consideration in postmenopausal women with a thorough risk discussion. [20]

For premenopausal women specifically, flibanserin and bremelanotide are the only two FDA-cleared pharmacologic options. Patients in South Dakota weighing cost should compare the $880 WAC for Addyi against Vyleesi's per-injection cost multiplied by anticipated monthly usage. A woman who anticipates two to four sexual encounters per month would pay $1,980 to $3,960 monthly for bremelanotide versus $880 for daily flibanserin, making flibanserin the lower-cost option at that frequency. [21]

Practical Cost-Reduction Pathway for South Dakota Patients

South Dakota patients face a clear set of choices, ordered roughly by cost:

First, check commercial insurance. Submit a prior authorization with DSM-5 HSDD documentation, FSFI and FSDS-R scores, and documented non-pharmacologic treatment. If approved, add the Sprout savings card to eliminate remaining cost-share. [17]

Second, if insured but not covered, apply the Sprout savings card anyway. For commercially insured patients whose plan denies coverage, the savings card may still apply to out-of-pocket cost at certain enrolled pharmacies.

Third, if uninsured or on Medicaid, contact Sprout's PAP directly or apply through NeedyMeds (needymeds.org). Income at or below 400 percent of the federal poverty level qualifies. [18]

Fourth, ask a licensed 503A compounding pharmacy in South Dakota for a compounded flibanserin formulation. A telehealth visit with a licensed South Dakota provider can generate the prescription the same day. Cost may fall between $60 and $200 per month. [10]

Finally, any patient starting flibanserin should receive counseling on the alcohol contraindication at the time of prescribing, per the FDA label. [1] Providers in South Dakota can confirm current REMS enrollment status for their pharmacy and practice at the Addyi REMS website.